Feature|Videos|August 5, 2026
Meet the Panelists of the Next-Generation Bioconjugation Panel
Key Takeaways
- Meet the panel of bioconjugate analytical experts.
- Gain insight into each of the panelists' backgrounds and expertise.
Bioconjugate analytical experts set up for a discussion on next-generation antibody drug conjugate (ADC) characterization.
Episodes in this series
Sponsored by Waters Corporation
Colette Quinn, Senior Director and Portfolio Owner at Waters Corporation, frames the growing complexity of the bioconjugate landscape, from antibody-drug conjugates to antibody-oligonucleotide conjugates and bioconjugate vaccines. She introduces the panel of subject matter experts joining the discussion: Deanna Hunt, Senior Director of Business Development at KBI Biopharma, Lance Cadang, a scientist in Genentech’s Synthetic Molecule Analytical Chemistry division and Zhengqi Zhang, Associate Principal Scientist at Merck & Co.
Related Content
